Tagged with Government

GGD The co-managing partner of one of Canada’s leading IP law firms discusses the landscape for intellectual property in the pharmaceutical industry in Canada today, the legislative challenges facing his clients, and the incentive schemes in place to bring innovation to Canada.  What have you seen as the key trends of…

Biotech City The director of Biotech City in Laval, close to Montreal, discusses the advantages brought on by the cluster effect, and how this has played out at Biotech City, a government funded cluster of 80 companies and over 5,000 employees.  Your background has a strong focus on business start-ups and development,…

Government Regulation As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate need for better legislation in this area for the benefit of patients, and the misconceptions of treating Canada as a…

Bavarian Nordic   If there is one thing that successful Danish companies have in common with one another, it is the clear recognition of abundant opportunities outside the motherland. “Danish companies’ strengths lie in their ability to build on what they have inherited from Denmark but to also look outward and be…

Generics Calvin Tsai and Jack Wu talk about their two-pronged international approach through pharmaceuticals and nutricare. The head of the nutricare business elaborates on the challenge of introducing milk products to the Asian market in the current climate, and the head of the pharma business explains the company’s long-term strategy for…

Government Regulation An interesting perspective on the Canadian market, and its opportunities and challenges in drug registration on a regional level from the President of Triton Pharma, a company dedicated to bringing unique drugs into the country in the areas of women’s health, dermatology and urology.   What have been some of…

Government Regulation   President Santos appointed economist Alejandro Gaviria as the new Minister of Health and Social Protection in September 2012. Gaviria’s priority has been to create health reform that would introduce the next episode of Colombia’s payer system, following the introduction of Law 100 in 1993, which extended health coverage to…

government relations Minister Marceau addresses the changes in policy in Quebec relating to the pharmaceutical and life sciences sectors, and the incentives in place to make the state an attractive place for the future of the pharmaceutical industry.   According to the Economic and Financial Profile of Quebec 2012, Quebec allocated 2.61…

government relations A perspective from Canada’s national health body on the future of medicine in the 21st century, from the shift to personalized medicine to streamlining regulatory and approval processes, removing duplication from international partners and utilizing modern communications technology to improve transparency and efficiency. Could you provide a brief overview of…

CSR The President & CEO of Sanofi Canada talks candidly about the pros and cons of the current administrative setup of the Canadian healthcare sector; Concerto, an association in Quebec that puts innovative pharma alongside government and regulators, and the local implications of the global trend of diversification in Big Pharma.…

Basic Research A leading figure in the Taiwanese pharmaceutical sector, Lee divulges the practicalities behind ECFA, the free trade agreement that was signed between China and Taiwan in 2010 but has not yet come into full force; questions whether a lack of multinational investment has been a major disadvantage for Taiwan; explains…

government relations   Under the administration of President Juan Manuel Santos, Colombia is focusing on bolstering the commercial sector. Thanks to the ratification of free trade agreements with 14 countries around the world since 2011, including the United States, foreign direct investment reached a record high of COP 29 trillion ($16 billion)…